VBI Vaccines updates on glioblastoma vax progress; Scripps team nets $1.6M for heroin addiction vaccine;

> Cambridge, MA-based VBI Vaccines ($VBIV) said data confirm the "desired integrity and quality" of its candidate glioblastoma vaccine; it has a pre-IND meeting with the FDA in the first half of 2016. Release

> A team at The Scripps Research Institute received $1.6 million through the Translational Avant-Garde Award program to work on a vaccine to combat heroin addiction. Report

> The Sabin Vaccine Institute, through its Product Development Partnership, teamed up with King Saud University to grow vaccine research capabilities in the Middle East. Report

> Baltimore, MD-based Vaccinogen signed on with Dublin City University to get its hands on the biotechnology analysis platform DiCast. Report

> Memphis, TN-based Hapten Sciences announced it's commencing trials of its poison ivy vaccine candidate. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.